NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

Area of Science:

• Gynecologic Oncology
• Clinical Practice Guidelines
• Cancer Treatment

Background:

• Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer mortality in the US.
• Survival rates for EOC remain low, with less than 50% of patients surviving beyond 5 years.
• Current treatment protocols require regular updates to incorporate emerging research and therapeutic advancements.

Purpose of the Study:

• To summarize key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Ovarian Cancer.
• To highlight revised recommendations for chemotherapy in elderly patients or those with comorbidities.
• To introduce a new treatment algorithm for recurrent low-grade serous carcinoma (LGSC) and updated molecular analysis applications.

Main Methods:

• The study summarizes discussions from a panel of experts on NCCN Guidelines.
• It focuses on recent revisions to diagnostic, evaluation, treatment, and follow-up recommendations.
• Key updates include chemotherapy alternatives, LGSC recurrence, and molecular profiling.

Main Results:

• Revised chemotherapy regimens are recommended for advanced-age patients and those with comorbidities.
• A new algorithm for recurrent LGSC incorporates emerging research and novel agents.
• Updated guidance on the application of tumor molecular analysis in ovarian cancer management is provided.

Conclusions:

• The updated NCCN Guidelines for Ovarian Cancer offer improved treatment strategies.
• These revisions address critical needs in managing advanced-age patients, recurrent LGSC, and utilizing molecular diagnostics.
• The guideline updates aim to enhance patient outcomes in epithelial ovarian cancer.